Please review the ACIP schedule example to see how MenQuadfi can be an option for your immunization goals.


MenQuadfi should not be administered to anyone who has had a severe allergic reaction to any component of the vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine.

Appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following the administration of the vaccine.

Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses to MenQuadfi. Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (eg, eculizumab) are at increased risk for invasive disease caused by N meningitidis, including invasive disease caused by serogroups A, C, W, and Y, even if they develop antibodies following vaccination with MenQuadfi.

Syncope can occur following, or even before, vaccination with MenQuadfi. Procedures should be in place to prevent falling and injury and to manage syncope.

Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to give MenQuadfi to persons with a history of GBS should take into account the expected benefits and potential risks.

Immunization with MenQuadfi does not substitute for routine tetanus immunization.

Vaccination with MenQuadfi may not protect all vaccine recipients.

The most common adverse reactions following a primary dose of MenQuadfi in individuals 2 years of age and older include pain at the injection site; myalgia, headache, and malaise. Other common adverse reactions in children 2 through 9 years of age include erythema and swelling at the injection site. In adolescents and adults, rates of solicited adverse reactions following a booster dose were comparable to those observed following primary vaccination. Other adverse reactions may occur.

Please see the full Prescribing Information for MenQuadfi.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

ACIP = Advisory Committee on Immunization Practices; MenABCWY = N meningitidis serogroups A, B, C, W, and Y; MenACWY = N meningitidis serogroups A, C, W, and Y; MenB = meningitis B; SCDM = shared clinical decision making.


  1. Collins J; ACIP Meningococcal Vaccines Work Group. National Center for Immunization and Respiratory Diseases. Centers for Disease Control and Prevention. Summary of EtR and proposed recommendations for Pfizer’s MenABCWY vaccine. October 25, 2023. Accessed March 15, 2024.
  2. About meningococcal vaccines. Centers for Disease Control and Prevention. Last Reviewed November 20, 2023. Accessed March 19, 2024.

Back to the top

This site is intended for U.S. Healthcare Professionals Only.

MAT-US-2007152-v7.0-04/2024 Last Updated: 04/2024